Ideaya Biosciences (IDYA) announced that Douglas Snyder, joined the company as its senior VP, general counsel on September 18. Snyder most recently served as executive VP, chief legal officer and secretary at GW Pharmaceuticals (GWPH) from 2017 to 2022 through the $7.2B acquisition by Jazz Pharmaceuticals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences price target raised to $68 from $63 at Stifel
- Ideaya Biosciences price target lowered to $58 from $60 at Citi
- Ideaya Biosciences removed from Analyst Focus List at JPMorgan
- Ideaya Biosciences price target lowered to $66 from $69 at JPMorgan
- Ideaya Biosciences price target lowered to $53 from $60 at Oppenheimer